13G Filing: Adage Capital Management and Advaxis Inc. (ADXS)

Page 8 of 10

Page 8 of 10 – SEC Filing

Item 2(e). CUSIP NUMBER
007624208
Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
(a) ¨ Broker or dealer registered under Section 15 of the Act;
(b) ¨ Bank as defined in Section 3(a)(6) of the Act;
(c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
(d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
(e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) ¨

An employee benefit plan or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F);

(g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
(h) ¨

A savings association as defined in Section 3(b)
of the Federal Deposit Insurance Act;

(i) ¨

A church plan that is excluded from the definition
of an investment company under Section 3(c)(14) of the Investment Company Act;

(j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
(k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
please

specify the type of institution: Not applicable .

Item 4. OWNERSHIP
A. Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C. and Adage Capital Advisors, L.L.C.
(a) Amount beneficially owned:  4,700,043
(b) Percent of class: 11.45%.  The percentages used herein and in the rest of this Schedule 13G/A are calculated based upon 41,065,835 shares of Common Stock issued and outstanding as of August 31, 2017, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended July 31, 2017 filed with the Securities and Exchange Commission on September 11, 2017.
(c) (i)     Sole power to vote or direct the vote:  0
(ii)    Shared power to vote or direct the vote: 4,700,043
(iii)   Sole power to dispose or direct the disposition:  0
(iv)   Shared power to dispose or direct the disposition of:  4,700,043

Follow Ayala Pharmaceuticals Inc. (NASDAQ:ADXS)

Page 8 of 10